26 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
13 Sep 23
Notice of Annual General Meeting of Shareholders
4:42pm
Law
No
Total Number of Directors
Female
Male
Non-Binary
Did Not Disclose Gender
Part I: Gender Identity
Directors
Part II: Demographic Background
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
2 Aug 23
Report of Foreign Private Issuer
8:05am
to a mortality rate of 3.8%−8.9% for age- and gender-severe COVID-19-matched patients, and 39%−55% for critical patients.
Average duration
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
5 Oct 22
Notice of Annual General Meeting of Shareholders
3:00pm
of Directors
Part I: Gender Identity
Female
Male
Non-Binary
Did Not
Disclose
Gender
Directors
Part II: Demographic Background
Underrepresented Individual
6-K
EX-99.1
cs9ccn247ie
4 Oct 21
Report of Foreign Private Issuer
8:00am
424B5
56s9exa
10 Feb 21
Prospectus supplement for primary offering
5:22pm
424B5
elbzp n69sfttuer
9 Feb 21
Prospectus supplement for primary offering
4:56pm
6-K
EX-99.1
0t9ez2
3 Feb 21
Current Report
7:55am
6-K
EX-99.1
fkenil
21 Dec 20
Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on medRxiv
8:02am
6-K
EX-99.1
so3f0 ug5hc8ei0eet
3 Nov 20
Current report (foreign)
9:14am
6-K
EX-99.1
hvvutn
28 May 20
Report of Foreign Private Issuer
9:25am
6-K
EX-99.1
6nek86pyuwvv d5t0jih
18 Mar 20
Enlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis
8:26am
6-K
EX-99.1
q2qbp3lc 2k2
19 Feb 19
Asset Purchase Agreement
4:57pm
6-K
EX-99.2
jp5s 92nrqrr
6 Dec 18
Amended Notice of Annual and Extraordinary General Meeting of the Shareholders
4:43pm